CD10 expression in diffuse large B-cell lymphomas does not influence survival

Fabiani, Bettina; Delmer, Alain; Lepage, Éric; Guettier, Catherine; Petrella, Tony; Brière, Josette; Penny, Anne-Marie; Copin, Marie‐Christine; Diébold, J; Reyes, F; Gaulard, Philippe; Molina, Thierry Jo; l’Adulte, Groupe d’Etudes des Lymphomes de

doi:10.1007/s00428-004-1129-7

Cited by 32 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies that applied the same cutoff value of 10% reported a lower frequency of positive expression of CD10 [19% (Braaten et al, 2003), 34% (Fabiani et al, 2004), 43% (Xu et al, 2001), and 51% (Linderoth et al, 2003)] Other studies, using the 20%, 25%, 30% and 50% cutoff values reported a wide range of CD10 expression in DLBCL tumors (2 to 92%) (e.g. Harada et al, 1999;Ohshima et al, 2001;Pileri et al, 2003;Camilleri-Broet et al, 2006).…”

Section: Discussionmentioning

confidence: 96%

“…However, other studies boasted respectable sample sizes of CD10 positive patients (ranging from 27 to 63) (Colomo et al, 2003;Linderoth et al, 2003;Fabiani et al, 2004;Liu et al, 2008) and still did not find a significant association between CD10 expression and DLBCL survival.…”

Section: Discussionmentioning

confidence: 97%

“…Tzankov et al, 2003;Chang et al, 2004;Hans et al, 2004;Hoffmann et al, 2005), seven studies did not report any significant difference (e.g. Braaten et al, 2003;Fabiani et al, 2004;Oh and Park, 2006;Liu et al, 2008), and two studies reported a statistically significant reduction of OS in association with positive BCL6 expression in DLBCL patients (Uherova et al, 2001;Xu et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies reported no prognostic value of this marker (Fabiani et al, 2004;Hans et al, 2004;Oh and Park, 2006). while others reported that the positive expression of CD10 was associated with better OS (Oshima et al, 2001;Hans et al, 2004;Sjo et al, 2007), and poor OS (Uherova et al, 2001;Xu et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes -germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Thirty-three percent positivity of CD10 was similar to previous reports. 11,12,14,24,29,30 The misclassification rate for the modified classification was 14% in relation to the Hans algorithm and 16% in relation to the Muris algorithm. According to Kappa statistics, the mea- …”

Section: Patient Characteristicsmentioning

confidence: 93%

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

Nyman

Jerkeman

Karjalainen–Lindsberg

et al. 2009

Modern Pathology

View full text Add to dashboard Cite

Gene expression profiling studies initially enabled diffuse large B-cell lymphoma to be divided into germinal center and activated B-cell-like subtypes, which define high-and low-risk patient groups when treated with chemotherapy. Attempts to reproduce the prognostic classification immunohistochemically have, however, provided inconsistent results. The aim of this study was to determine whether modified immunohistochemical classification of cell of origin focusing on activated B-cell-like markers could be used to predict the outcome of immunochemotherapy-treated diffuse large B-cell lymphoma patients. The expression of CD10, Bcl-6, MUM1/ IRF4, Bcl-2, and FOXP1 was determined immunohistochemically from 88 samples of diffuse large B-cell lymphoma patients treated uniformly with R-CHOP. When the modified classification using MUM1/IRF4 and FOXP1 positivities as activated B-cell-like markers was applied to distinguish the patients between the activated B-cell-like and other diffuse large B-cell lymphoma subtypes, a significantly worse outcome was seen for the patients with the activated B-cell-like phenotype (3-year failure-free survival 63 vs 82%, P ¼ 0.048, overall survival 69 vs 85%, P ¼ 0.110). Similarly, according to the Muris algorithm, the group 2 patients representing Bcl-2-positive post-germinal center patients showed an inferior outcome in comparison to the group 1 patients (failure-free survival 59 vs 81%, P ¼ 0.041, overall survival 67 vs 82%, P ¼ 0.159). In contrast, when the classification of the same cohort was performed according to the Hans algorithm, no significant difference in survival was observed between the germinal center and non-germinal center patients. In conclusion, the data suggest that both the modified activated B-cell-like and Muris classifications define the non-germinal center phenotype as an adverse risk factor in R-CHOP-treated diffuse large B-cell lymphoma patients. Modern Pathology (2009Pathology ( ) 22, 1094Pathology ( -1101 doi:10.1038/modpathol.2009 published online 15 May 2009 Keywords: diffuse large B-cell lymphoma; MUM1/IRF4; activated B-cell-like; R-CHOP; prognosis Diffuse large B-cell lymphoma is the most common lymphoma subtype, accounting for 30% of all nonHodgkin's lymphomas. It shows an aggressive clinical course, and comprises a heterogeneous group of lymphomas in terms of morphology, immunophenotype and molecular abnormalities.

show abstract

References

2021

Flow Cytometry of Hematological Malignancies

View full text Add to dashboard Cite

CD10 expression in diffuse large B-cell lymphomas does not influence survival

Cited by 32 publications

References 28 publications

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

References

Contact Info

Product

Resources

About